Arrowhead Pharmaceuticals Appoints Daniel Apel As Chief Financial Officer
04/15/25, 8:28 PM
Location
pasadenaIndustry
manufacturing
Position
chief financial officer
Effective May 13, 2025, Daniel Apel will succeed Ken Myszkowski as the Chief Financial Officer of Arrowhead Pharmaceuticals. Ken Myszkowski is retiring after 16 years but will assist in the transition.
Company Info
Location
pasadena, california, united states
Additional Info
Arrowhead Pharmaceuticals develops medicines that treat intractable diseases by silencing the genes that cause them. Using a broad portfolio of RNA chemistries and efficient modes of delivery, Arrowhead therapies trigger the RNA interference mechanism to induce rapid, deep, and durable knockdown of target genes. RNA interference, or RNAi, is a mechanism present in living cells that inhibits the expression of a specific gene, thereby affecting the production of a specific protein. Arrowhead’s RNAi-based therapeutics leverage this natural pathway of gene silencing.